Clinical Trials Logo

Filter by:
NCT ID: NCT03276585 Enrolling by invitation - Depression Clinical Trials

Night in Japan Home Sleep Monitoring Study

NinJaSleep
Start date: September 6, 2017
Phase:
Study type: Observational

The investigators hypothesized that depression is associated with home sleep EEG, subjective sleepiness and insomnia symptoms. To test this, the investigators plan to perform sleep examination with single channel EEG, in combination with questionnaire survey for insomnia, sleepiness, depression and job stress to Koka city government employees.

NCT ID: NCT03250377 Enrolling by invitation - Epilepsy Clinical Trials

A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization

Start date: August 5, 2017
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate the long-term safety and tolerability of Brivaracetam (BRV) in focal epilepsy subjects with partial seizures and to evaluate the maintenance of efficacy of BRV over time.

NCT ID: NCT02873013 Enrolling by invitation - Prostate Cancer Clinical Trials

Asia Study Group of Prostate Cancer (A-CaP Study)

Start date: March 2016
Phase:
Study type: Observational

This study will target patients who have received a histopathological diagnosis of prostate cancer and who are undergoing treatment in various forms, including active PSA surveillance, surgical treatment, radiotherapy, endocrine therapy, and chemotherapy. The study will survey information about the patient at time of diagnosis, clinical staging, details of initial treatment, status of disease progression, and prognosis at the end point of the study. The purpose of the study is to clarify distribution of staging, the actual status of treatment choices and treatment outcomes.

NCT ID: NCT02670213 Enrolling by invitation - Clinical trials for Congenital Bleeding Disorder

A Study of Safety and Effectiveness of NovoThirteen® (rFXIII) During Treatment of Congenital FXIII Deficiency in Japan

Start date: March 16, 2016
Phase:
Study type: Observational

This study is conducted in Asia. Tha aim of this study is to investigate Safety and Effectiveness of NovoThirteen® (rFXIII) during treatment of congenital FXIII deficiency in Japan.

NCT ID: NCT02565264 Enrolling by invitation - Ulcer Clinical Trials

Effect of Plasma Derived Exosomes on Cutaneous Wound Healing

Start date: September 2015
Phase: Early Phase 1
Study type: Interventional

This study is an open prospective clinical trial. The objective is to evaluate the effect of autologous exosomes rich plasma on cutaneous wound healing. The participants are patients with intractable cutaneous ulcers (e.g. rheumatic disease, peripheral arterial disease, chronic venous insufficiency, decubitus or burns). The participants will be treated autologous exosomes rich plasma every day for 28 days. The cutaneous wound healing will be evaluated by the length, width and depth of the wound.

NCT ID: NCT02456038 Enrolling by invitation - Hypophosphatasia Clinical Trials

Safety and Efficacy of Asfotase Alfa in Patients With Hypophosphatasia (HPP)

Start date: August 2014
Phase: Phase 2
Study type: Interventional

The aim of this study is to assess safety and efficacy of Asfotase Alfa (ALXN1215) in patients with hypophosphatasia

NCT ID: NCT02237534 Enrolling by invitation - Clinical trials for Renal Insufficiency, Chronic

Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia

LAVALIER
Start date: September 2014
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare the effect of lanthanum carbonate and calcium carbonate on the progression of coronary calcification and vascular endothelial dysfunction.

NCT ID: NCT01898780 Enrolling by invitation - Clinical trials for Patients Who Undergo Pancreatoduodenectomy

Horizontal Mattress vs. Interrupted Suture in Surgical Techniques of Pancreaticojejunostomy

Start date: June 2013
Phase: Phase 3
Study type: Interventional

The aim of this study is to verify that the frequency of pancreatic fistula (ISGPF grade B and C) in horizontal mattress suture are lower than in interrupted suture during pancreaticojejunostomy in pancreatoduodenectomy by randomized clinical trial.

NCT ID: NCT01846949 Enrolling by invitation - Liver Cirrhosis Clinical Trials

Surveillance Study for HCC by Combining Biomarkers With Imaging (ALDUS)

ALDUS
Start date: May 2013
Phase:
Study type: Observational

This study is intended to be a prospective observational study at multiple sites, not a randomized controlled trial (RCT). The uses of the biomarkers has been approved by government regulations and adopted for surveillance programs in some countries, thus an RCT which compares patients followed by US alone with patients followed by both US and the biomarkers would raise an ethical conflict, especially in countries where the biomarkers have been routinely used. For this study, enrolled patients will be followed by US and the biomarkers at regular intervals and classified after completing the study to evaluate the clinical effectiveness of the biomarkers. The comparisons of sensitivity, specificity, and other parameters with respect to tumor characteristics will be made among US alone, the biomarkers, and combined use of US and the biomarkers. Also economical effectiveness of using the biomarkers will be investigated in this study. Requirement status is monitored every month.

NCT ID: NCT01804686 Enrolling by invitation - Clinical trials for Chronic Lymphocytic Leukemia

A Long-term Extension Study of PCI-32765 (Ibrutinib)

CAN3001
Start date: September 9, 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been completed according to the parent protocol, are actively receiving treatment with ibrutinib, and who continue to benefit from ibrutinib treatment.